Waldenstrom's Macroglobulinemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory B-cell Malignancies.
Conditions: CLL/SLL; Waldenstrom Macroglobulinemia; Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Hairy Cell Leukemia Intervention: Drug: LP-168 Sponsor: Newave Pharmaceutical Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2021 Category: Research Source Type: clinical trials

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Conditions: CLL/SLL; Waldenstrom Macroglobulinemia; Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Hairy Cell Leukemia Intervention: Drug: LP-168 Sponsor: Newave Pharmaceutical Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2021 Category: Research Source Type: clinical trials

Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Conditions: Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Waldenstrom Macroglobulinemia Intervention: Sponsors: Assistance Publique - Hôpitaux de Paris; INSERM UMR 1163 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2021 Category: Research Source Type: clinical trials